In brief
- Arizona is allocating $5 million from the state Department of Health to an ibogaine clinical trial.
- The study, led by the Barrow Neurological Institute, will evaluate the substance for chronic traumatic brain injury (TBI).
- It will be a randomized, placebo-controlled phase 1/2 trial with 40 participants; the August release hoped for first enrollment in 2027, without confirming that forecast here.
The Arizona Department of Health has awarded $5 million to the Barrow Neurological Institute in Phoenix to launch a clinical trial investigating ibogaine as a potential treatment for the persistent symptoms of traumatic brain injury (TBI). The announcement, made public on August 5, describes a grant received by Barrow; it does not itself establish a state funding ranking.
An announced placebo-controlled design
The phase 1/2 study will be led by neuropsychiatrist Anna Burke alongside a multidisciplinary team at Barrow, in collaboration with the Barrow Neuro Analytics Center and Arizona State University (ASU). It will recruit 40 people with chronic symptoms resulting from a TBI, who will be randomly assigned to receive ibogaine or a placebo in a double-blind design—the standard method for separating the substance’s actual effect from the placebo effect. In August, Barrow hoped to enroll the first participant in 2027. This review does not confirm current enrollment or a results date.
The release identifies an Arizona health-department grant. Budget documents and specific individuals’ roles in approving it were not reviewed here.
Why TBI and the interest behind it
Susan Criswell, medical director of clinical research at Barrow, notes that approximately half of the people who suffer a traumatic brain injury experience lingering symptoms or incomplete recovery beyond six months—a therapeutic gap that current options address poorly. Interest in ibogaine in this field is supported by previous open-label, non-controlled studies involving U.S. veterans with both TBI and post-traumatic stress, in which a single dose was associated with sustained improvements in symptoms, cognitive function, and quality of life. In the U.S., ibogaine remains classified as a Schedule I substance, the same category as heroin or LSD, which has until now driven those seeking treatment to clinics in Mexico and other countries. The release places the announcement in a wider research context; this review does not verify other states’ appropriations or federal funding mechanisms.
What this implies
Announced funding does not establish efficacy or safety, and the release contains no outcomes from this trial. Evaluation must distinguish hypotheses from open-label studies from randomized results. The August release does not confirm current recruitment status or a results date. Details of cardiac monitoring for this trial are not detailed in the inspected release; this review did not read the complete protocol and cannot certify its cardiac criteria or infer they do not exist.
Related previous coverage: Colorado opens the door to regulated ibogaine starting in August.
Source
- Barrow Neurological Institute. Arizona Grants $5M to Barrow for Clinical Trial of Ibogaine in TBI. Barrow Neurological Institute, August 5, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
